These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31787103)

  • 1. Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy.
    Padovani A; Benussi A; Cotelli MS; Ferrari C; Cantoni V; Dell'Era V; Turrone R; Paghera B; Borroni B
    Alzheimers Res Ther; 2019 Dec; 11(1):95. PubMed ID: 31787103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease.
    Benussi A; Alberici A; Ferrari C; Cantoni V; Dell'Era V; Turrone R; Cotelli MS; Binetti G; Paghera B; Koch G; Padovani A; Borroni B
    Alzheimers Res Ther; 2018 Sep; 10(1):94. PubMed ID: 30227895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation.
    Padovani A; Benussi A; Cantoni V; Dell'Era V; Cotelli MS; Caratozzolo S; Turrone R; Rozzini L; Alberici A; Altomare D; Depari A; Flammini A; Frisoni GB; Borroni B
    J Alzheimers Dis; 2018; 65(1):221-230. PubMed ID: 30010131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    van der Zande JJ; Gouw AA; van Steenoven I; van de Beek M; Scheltens P; Stam CJ; Lemstra AW
    Neurology; 2020 Aug; 95(6):e662-e670. PubMed ID: 32636325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification accuracy of TMS for the diagnosis of mild cognitive impairment.
    Benussi A; Grassi M; Palluzzi F; Cantoni V; Cotelli MS; Premi E; Di Lorenzo F; Pellicciari MC; Ranieri F; Musumeci G; Marra C; Manganotti P; Nardone R; Di Lazzaro V; Koch G; Borroni B
    Brain Stimul; 2021; 14(2):241-249. PubMed ID: 33453454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment.
    Falgàs N; Tort-Merino A; Balasa M; Borrego-Écija S; Castellví M; Olives J; Bosch B; Férnandez-Villullas G; Antonell A; Augé JM; Lomeña F; Perissinotti A; Bargalló N; Sánchez-Valle R; Lladó A
    Eur J Neurol; 2019 Aug; 26(8):1098-1104. PubMed ID: 30793432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.
    Kokkinou M; Beishon LC; Smailagic N; Noel-Storr AH; Hyde C; Ukoumunne O; Worrall RE; Hayen A; Desai M; Ashok AH; Paul EJ; Georgopoulou A; Casoli T; Quinn TJ; Ritchie CW
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010945. PubMed ID: 33566374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia.
    Cantone M; Di Pino G; Capone F; Piombo M; Chiarello D; Cheeran B; Pennisi G; Di Lazzaro V
    Clin Neurophysiol; 2014 Aug; 125(8):1509-32. PubMed ID: 24840904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.
    Boström G; Freyhult E; Virhammar J; Alcolea D; Tumani H; Otto M; Brundin RM; Kilander L; Löwenmark M; Giedraitis V; Lleó A; von Arnim CAF; Kultima K; Ingelsson M
    J Alzheimers Dis; 2021; 81(2):629-640. PubMed ID: 33814444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.
    Benussi A; Di Lorenzo F; Dell'Era V; Cosseddu M; Alberici A; Caratozzolo S; Cotelli MS; Micheli A; Rozzini L; Depari A; Flammini A; Ponzo V; Martorana A; Caltagirone C; Padovani A; Koch G; Borroni B
    Neurology; 2017 Aug; 89(7):665-672. PubMed ID: 28747446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early differentiation of dementia with Lewy bodies and Alzheimer's disease: Heart rate variability at mild cognitive impairment stage.
    Kim MS; Yoon JH; Hong JM
    Clin Neurophysiol; 2018 Aug; 129(8):1570-1578. PubMed ID: 29883835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
    Chiba Y; Fujishiro H; Iseki E; Kasanuki K; Sato K
    J Neuroimaging; 2019 Nov; 29(6):712-720. PubMed ID: 31199036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.